Scientific programme

Industry exhibition and Lunch

AstraZeneca Lunch Symposium

From ground-breaking medical evidence to change in clinical practice

12:05 - 12:10

Challenges and opportunities with CKD in primary care

PCPs, video

12:10 - 12:20

The standard of care for CKD patients in primary care is changing: are we ready for that?

Professor Peter Rossing, Denmark

12:20 - 12:40

From evidence to clinical practice: key highlights and first experiences.

Professor David Wheeler, UK

12:40 - 12:50

Strategical working group of Finnish Society of Nephrology: Early detection and management of CKD

Associate Professor Satu Mäkelä, Finland

12:50 - 13:00

Panel discussion and Q&A

All

Hansa BioPharma Symposium

Towards equity for highly sensitised patients in kidney transplantation

Chair: Dr Margrét B Andrésdóttir 

Introduction

Dr Margrét B. Andrésdóttir, National University Hospital of Iceland, Reykjavík, Iceland

Transplant options for very highly sensitised patients

Dr Nicholas Topey, Cambridge Transplant Unit, Cambridge, UK

The challenge of highly sensitised patients in the Nordics - early experience of imlifidase in Finland

Dr Ilkka Helanterä, Helsinki University Hospital, Helsinki, Finland

Discussion and questions

All

Closing remarks

Dr Margrét B Andrésdóttir

Industry exhibition and Lunch

Chiesi Sponsored Lunch Symposium

New opportunities in the treatment of Fabry disease

Fabry disease in the Nordics - current unmet need with renal focus

Fabry nephropathy – new treatment approaches

Where do we stand and where do we go?

Speakers:
Camilla Tøndel, Professor, MD PhD Pediatric Nephrology Haukeland University Hospital
Ulla Feldt-Rasmussen, Professor, MD, DMSc Medical Endocrinology and Metabolism Copenhagen University Hospital
Irene Koulinska, Medical Director, Inborn Errors of Metabolism ‑ Rare Diseases Chiesi Global Rare Diseases

INVITATION

Free Communications - best 5 abstracts

15:00 - 15:10

O1 - Survival, hospitalization and infectious complications in urgent-start PD compared with urgent-start HD

Jonna Virtanen, Finland

15:10 - 15:20

O2 - Incident warfarin treatment versus no anticoagulants in patients with non-valvular atrial fibrillation and CKD G3-G5D.

Frida Welander, Sweden

 15:20 - 15:30

O3 - The Borg scale for prescribing and monitoring intensity of self-administered balance and strength exercise is safe and efficient in patients with CKD

Philippa Svensson, Sweden

15:30 - 15:40

O4 -  Combining dapagliflozin and finerenone has an additive effect on albuminuria in non-diabetic CKD: An open label randomized clinical trial

Frederik Husum Mårup, Denmark

 15:40 - 15:50

O5 - Community-acquired acute kidney injury: Causes and risk factors

Telma Huld Ragnarsdóttir, Iceland

Astellas Symposium

A practical Approach: Why and How to Use EVRENZO

Dr David Wheeler, UK

We are happy to announce that one of the leading European experts in nephrology, Dr David Wheeler will be giving this talk about the practical implementation of roxadustat.

DOWNLOAD BROCHURE

CSL Vifor Symposium

New treatment modalities for AAV and CKD-associated Pruritus

9:30-9:35

Welcome and introduction

Associate Professor Gunnar Tómasson, Landspítali - The National University Hospital of Iceland

9:35-10:00

New aspects in ANCA associated vasculitis

Ragnar Gunnarsson, MD PhD, Oslo University Hospital Rikshospitalet

10:00-10:25

An opportunity to improve CKD-associated Pruritus: Sharing clinical experience of difelikefalin

Professor Gert Mayer, Medical University Innsbruck, Austria

10:25-10:30

Panel discussion and Q&A

All